key: cord-0027711-0bdtq748
authors: Qi, Sudong; Gao, Bin; Zhu, Shunyi
title: A Fungal Defensin Inhibiting Bacterial Cell-Wall Biosynthesis with Non-Hemolysis and Serum Stability
date: 2022-02-10
journal: J Fungi (Basel)
DOI: 10.3390/jof8020174
sha: 1a5b84dcf854abe05ac97d3c23ef841fd8f39c17
doc_id: 27711
cord_uid: 0bdtq748

Defensins are a class of cationic disulfide-bridged antimicrobial peptides (AMPs) present in many eukaryotic organisms and even in bacteria. They primarily include two distinct but evolutionarily related superfamilies (cis and trans). Defensins in fungi belong to the members of the cis-superfamily with the cysteine-stabilized α-helical and β-sheet fold. To date, many fungal defensin-like peptides (fDLPs) have been found through gene mining of the genome resource, but only a few have been experimentally characterized. Here, we report the structural and functional characterization of Pyronesin4 (abbreviated as Py4), a fDLP previously identified by genomic sequencing of the basal filamentous ascomycete Pyronema confluens. Chemically, synthetic Py4 adopts a native-like structure and exhibits activity on an array of Gram-positive bacteria including some clinical isolates of Staphylococcus and Staphylococcus warneri, a conditioned pathogen inhabiting in human skin. Py4 markedly altered the bacterial morphology and caused cytoplasmic accumulation of the cell-wall synthesis precursor through binding to the membrane-bound Lipid II, indicating that it works as an inhibitor of cell-wall biosynthesis. Py4 showed no hemolysis and high mammalian serum stability. This work identified a new fungal defensin with properties relevant to drug exploration. Intramolecular epistasis between mutational sites of fDLPs is also discussed.

As the effectors of innate immunity in multicellular organisms, antimicrobial peptides (AMPs) establish the first-line defense in the fight against infections from a variety of microorganisms such as bacteria, fungi, viruses, and protozoa [1, 2] . Due to their evolutionary success as host defense molecules across the history of multicellular organisms and less susceptibility to microbial resistance, AMPs have been considered as promising alternatives to conventional antibiotics in the age of resistance [2] [3] [4] . They are mostly small cationic molecules of <100 amino acids and often bind to an accessible negatively charged microbial membrane via their positively charged residues to cause irreversible membrane damage and cellular death [2, 5] . Some AMPs work as a metabolic inhibitor to interact with non-membrane bacterial targets such as Lipid II, outer membrane proteins, and intracellular components (e.g., DNA and proteins) to inhibit their growth [4, 6, 7] . AMPs markedly differ in sequence and structure and are roughly divided into three major categories on the basis of their amino acid composition and structural types: (1) Linear α-helical AMPs that adopt a helical configuration when contacting microbial membrane, e.g., cecropins from insect hemolymph [8] , magainins from frog skins [2] , and LL-37 from human neutrophils [9] ; (2) Specific amino acid-rich linear AMPs that often lack a defined secondary structure (e.g., PR-39 from pigs [10] and metchnikowin and drosocin from Drosophila [11] );

The model structure of Py4 was obtained by introducing two point mutations (Q14K and G33A) into the plectasin structure (pdb entry 1ZFU) with Swiss-PdbViewer 4.1.0 followed by energy minimization with the GROMOS96 force-field in vacuo without the reaction field (https://spdbv.vital-it.ch/, accessed on 20 April 2021). This structure was used to dock with Lipid II, which is complexed with plectasin [24] by a template-based docking method [28] . The initial Py4-Lipid II complex was optimized by energy minimization using the Amber12: EHT force-field implemented in Molecular Operating Environment (MOE) 2019.0102.

For comparison purposes, 50 ns of MD simulations was performed for Py4 and plectasin with the GROMACS 2020.1 software package (http://www.gromacs.org/, accessed on 20 April 2021). The force-field used was the OPLS (Optimized Potential for Liquid Simulations)-AA/L all-atom force-field (2001 amino acid dihedrals) and TIP3P model for explicit water. Solvent shell thickness was 1.0 nm in a cubic box and the total charge of the simulated systems were neutralized by adding sodium or chloride ions. The system was subsequently equilibrated with NVT (number of particles, volume, and temperature) and NPT (number of particles, pressure, and temperature), in which all protein atoms were restrained to their initial position. Following these two equilibration stages, production MD was performed according to the method previously described [29] . Root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) were calculated with the trajectory analysis tools implemented in GROMACS 2020.1.

Py4 was chemically synthesized by Zhejiang Ontores Biotechnologies Co., Ltd. (Hangzhou, China) and its oxidized form was produced by air oxidization in an alkaline solution of N,N-diisopropylethylamine (pH8.0), which was further purified by reverse phase-high performance liquid chromatography (RP−HPLC). Its molecular weight (MW) was determined by MALDI−TOF (matrix-assisted laser desorption/ionization time of flight) mass spectrometry performed on MALDI−TOF/TOF Ultraflextreme TM (Bruker Daltonics, Bremen, Germany) using α-acyano-4-hydroxycinnamic acid (α-CHCA) as the matrix in the positive-reflection ion mode.

The secondary structure of Py4 was studied by CD spectroscopy analysis on a Chirascan Plus spectropolarimeter v.4.4.0 (Applied Photophysics Ltd., Leatherhead, Surrey, UK). The spectra were measured at room temperature from 185-260 nm by using a quartz cell of 1.0 mm thickness and the spectra from 190-260 nm were analyzed. Data were collected at 1 nm intervals with a scan rate of 2 nm/s and expressed as delta epsilon (cm −1 M −1 ) calculated as [θ × (MRW × 0.1)/(C × L)/3298], where θ is the ellipticity (in millidegrees), C is the concentration (in mg/mL), L is the pathlength (in cm), and MRW is the mean residue weight (in Da).

The inhibition-zone assay was used to quantify the antibacterial activity of Py4, as described previously [8, 19] . In brief, an overnight bacterial culture from a single colony was inoculated into fresh medium and grew to the late log-phase. A 10 µL aliquot of each culture was diluted in 6 mL pre-heated medium containing 0.8% agar. The mixture was spread on a 9-cm Petri dish, giving a depth of 1 mm. After settling, 3-mm wells were punched in the plate and then 2 µL peptide samples of different concentrations were added to each well. The agar plates were incubated overnight at indicated temperatures. A lethal concentration (C L ) was calculated from a plot of d 2 against log n, where d is the diameter (in cm) and n is the amount of sample applied in the well (in nmol). The plot is linear and thus C L can be calculated from the slope (k) and the intercept (m) of this plot. The formula used here was C L = 2.93/ak10 m/k , where a is the thickness of the bacterial plate and C L is in µM. In most cases, the calculated C L were comparable with the directly measured minimal inhibitory concentrations (MIC) via the broth micro-dilution assay [30] .

The membrane permeability assay was performed according to the method previously described [19] . Meucin-18 and Meucin-49, two known scorpion venom lytic peptides [31, 32] , were used as positive controls and vancomycin, a known bacterial cell-wall synthesis inhibitor without membrane-disruptive ability [19] as a negative control. Bacillus megaterium cells in 500 µL of phosphate buffered saline (PBS) (pH 7.3) were mixed with 1 µM propidium iodide (PI) for 5 min in the dark. Fluorescence was measured with the F-4500 FL spectrophotometer (Hitachi High-Tech Science Corporation, Tokyo, Japan). Once the basal fluorescence reached a constant value, peptides or vancomycin at 10 × C L were added, and changes in fluorescence arbitrary were monitored (λ exc = 525 nm; λ ems = 595 nm).

Curtobacterium luteum cells at the exponential growth phase were treated with 20 × C L (0.6 µM) of Py4 or 20 × vancomycin (2.0 µM) at 37 • C for 90 min. After centrifugation, bacterial pellets were fixed with 2.5% glutaraldehyde at 4 • C overnight, followed by washing three times with water. Dehydration was carried out with a series of graded ethanol solutions. Cells were then dried by a Leica EM CPD300 Automated Critical Point Dryer (Leica Microsystems, Wetzla, Germany) before being mounted on carbon tape and sputtered with a gold coating by a Leica EM SCD050. Images were visualized by using a FEI Quanta 450 scanning electron microscope (FEI, Hillsboro, OR, USA).

The cytoplasmic UDP-MurNAc-pentapeptide (abbreviated as UMP) accumulation experiment was carried out according to the method previously described [19, 33] . In brief, S. warneri cells were grown at 37 • C to an OD 600 of 0.5 in 40 mL broth medium and then the culture was supplemented with 130 µg/mL chloramphenicol to impede bacterial cell proliferation by blocking their protein synthesis. After 15 min of incubation, the culture was divided into three equal portions, and one portion was treated with Py4 (0.6 µM), the second with vancomycin (2.0 µM), and the third was used as an untreated control. UMP was extracted from the harvested cells following 30 min of incubation. UMP was identified by MALDI−TOF on MALDI−TOF/TOF Ultraflextreme TM (Bruker Daltonics, Bremen, Germany) using 2,5-dihydroxybenzoic acid (DHB) as the matrix in the negative-reflection ion mode.

Bio-affinity electrospray ionization mass spectrometry (ESI-MS) was used to study non-covalent interactions between Py4 and the S. warneri cell wall precursor-UMP according to the method previously described [19] . All components for interactions were dissolved in 25 mM ammonium acetate (pH5.2). Electrospray spectra were recorded with a Waters SynaptG2-Si mass spectrometer (Waters, Manchester, UK) and measurements were performed with positive ESI in resolution mode. Ions were scanned in a mass range of 500 to 2000 m/z with the following conditions: the capillary voltage at 1500 V; the cone voltage at 40 V; and the source block temperature at 30 • C. Spectra were recorded and processed by the software Masslynx4.1 (Waters, Manchester, UK).

Hemolytic activity of peptides against fresh erythrocytes from ICR mice (Mus musculus) was assayed according to the standard method [19] . Peptides were diluted with 0.9% NaCl to the indicated concentration. The percentage of hemolysis is determined as (A pep − A blank )/(A tot − A blank ) × 100, in which "A" represents absorbance measured at 570 nm. A blank and A pep were evaluated in the absence or presence of peptides. One hundred percent hemolysis (A tot ) was obtained in the presence of 1% Triton X-100. For the stability assay, Py4 was incubated in H 2 O or fresh mouse serum for the indicated times at 37 • C and their residual activity was measured by the inhibition-zone assay [19] .

Compared with plectasin, the natural variant Py4 has two point mutations at positions 14 and 33 ( Figure 1A ) that are respectively located on the α-helix (Q14K) and the Figure 1A ). These two mutations are interesting considering their mutational effects previously reported in plectasin. (1) Position 14. This site is not involved in direct interactions with both Lipid II and bacterial membrane [24] , but its mutation from the polar Qln to a cationic amino acid (Arg or Lys) conferred enhanced antibacterial activity in two engineered plectasin mutants (NZ2114 and MP1102) [34, 35] , suggesting that it belongs to a class of activity-modulating sites ( Figure 1A ). (2) Position 33. This site is rather unique since it exerts NMR (nuclear magnetic resonance) chemical shift-changes both upon the addition of the membrane mimicking dodecylphosphocholine (DPC) micelles and Lipid II [24] , highlighting its key role in conferring to both Lipid II and membrane binding ( Figure 1A ,B). Its functional importance is further strengthened by site-saturated mutagenesis, which showed that no amino acid substitutions at this position (Gly-33) resulted in activity against S. aureus [24] , indicating that this glycine is indispensable for the antibacterial function of plectasin. Intriguingly, in Py4, this position is occupied by an alanine instead of a glycine. In such a case, there would be two possibilities in terms of its activity: (1) Py4 would lack antibacterial activity due to the mutation, as observed in the plectasin Gly-33 mutants [24] ; and (2) if Py4 shows antibacterial activity, this suggests that the accompanying mutation at position 14 (Q14K) creates a new genetic background different to that of plectasin by epistasis [36] to maintain the activity. 

Compared with plectasin, the natural variant Py4 has two point mutations at positions 14 and 33 ( Figure 1A ) that are respectively located on the α-helix (Q14K) and the Cloop (G33A) ( Figure 1A ). These two mutations are interesting considering their mutational effects previously reported in plectasin. (1) Position 14. This site is not involved in direct interactions with both Lipid II and bacterial membrane [24] , but its mutation from the polar Qln to a cationic amino acid (Arg or Lys) conferred enhanced antibacterial activity in two engineered plectasin mutants (NZ2114 and MP1102) [34, 35] , suggesting that it belongs to a class of activity-modulating sites ( Figure 1A ). (2) Position 33. This site is rather unique since it exerts NMR (nuclear magnetic resonance) chemical shift-changes both upon the addition of the membrane mimicking dodecylphosphocholine (DPC) micelles and Lipid II [24] , highlighting its key role in conferring to both Lipid II and membrane binding ( Figure 1A ,B). Its functional importance is further strengthened by site-saturated mutagenesis, which showed that no amino acid substitutions at this position (Gly-33) resulted in activity against S. aureus [24] , indicating that this glycine is indispensable for the antibacterial function of plectasin. Intriguingly, in Py4, this position is occupied by an alanine instead of a glycine. In such a case, there would be two possibilities in terms of its activity: (1) Py4 would lack antibacterial activity due to the mutation, as observed in the plectasin Gly-33 mutants [24] ; and (2) if Py4 shows antibacterial activity, this suggests that the accompanying mutation at position 14 (Q14K) creates a new genetic background different to that of plectasin by epistasis [36] to maintain the activity. with two engineered mutants (NZ2114 and MP1102) included. Secondary structure elements (the cylinder for the α-helix and arrows for β-strands), loops and disulfide bridges are drawn according to the coordinates of plectasin (pdb entry 1ZFU). Residues of plectasin involved in interacting with Lipid II and bacterial membrane are shown, respectively, in blue and orange, with those implicated in both boxed [24] . Residues whose mutations diminished the activity are underlined once [24] . Mutational sites in Py4 and the engineered peptides are colored in red and underlined twice. (B) The functional surface of plectasin. Residues belonging to the Lipid II binding and membrane contact regions are shown by dots in blue and orange, respectively, with those belonging to both shown by spheres. Activitymodulating sites whose mutations improved the activity but not involved in Lipid II and membrane binding [24, 34, 35] are shown as red sticks. (C) The Py4 structure. The two mutation residues are shown as sticks in different colors. Secondary structure elements and three intercysteine loops are with two engineered mutants (NZ2114 and MP1102) included. Secondary structure elements (the cylinder for the α-helix and arrows for β-strands), loops and disulfide bridges are drawn according to the coordinates of plectasin (pdb entry 1ZFU). Residues of plectasin involved in interacting with Lipid II and bacterial membrane are shown, respectively, in blue and orange, with those implicated in both boxed [24] . Residues whose mutations diminished the activity are underlined once [24] . Mutational sites in Py4 and the engineered peptides are colored in red and underlined twice. (B) The functional surface of plectasin. Residues belonging to the Lipid II binding and membrane contact regions are shown by dots in blue and orange, respectively, with those belonging to both shown by spheres. Activitymodulating sites whose mutations improved the activity but not involved in Lipid II and membrane binding [24, 34, 35] are shown as red sticks. (C) The Py4 structure. The two mutation residues are shown as sticks in different colors. Secondary structure elements and three intercysteine loops are labeled. (D) Structural basis of Py4 interacting with Lipid II. The complex was built by templatebased molecular docking from the plectasin-Lipid II complex. Indicated in yellow dashed lines are hydrogens in the complex, in which involved amino acid residues and pyrophosphate moiety are labeled.

Using homology modeling combined with template docking, we built a theoretic complex between Py4 and Lipid II based on that of plectasin and Lipid II ( Figure 1C ,D). Analysis of the complex structure revealed that the conserved hydrogen bond network mediating the interaction of plectasin with Lipid II [24] also exists in the Py4-Lipid II complex. The residues involved in the network include the N-terminus, His-18, Phe-2, Gly-3, Cys-4, and Cys-37 of Py4 and the D-γ-glutamate and the pyrophosphate moiety of Lipid II ( Figure 1D ), suggesting that Py4 would also target Lipid II if it has an antibacterial activity.

To investigate the potential structural effects of the mutations on Py4, we carried out molecular dynamics (MD) simulations to compare changes in structural stability and flexibility between Py4 and plectasin. The results showed that after 25 ns of simulations, their root-mean-square deviation (RMSD) curves began to deviate remarkably from each other over time (Figure 2A ). Further analyses of individual loops revealed that Py4 and plectasin both have similar RMSDs in the N-loop (residues 5-12) and the M-loop (residues [22] [23] [24] [25] [26] [27] whereas larger deviation occurred after 25-ns simulations in the C-loop (residues 31-36) (0.1 nm in Py4 and 0.4 nm in plectasin) (Figure 2A ). This indicates that this loop essentially contributes to the mutation-elicited structural deviation. In plectasin, this loop connects the C-terminal β2 and β3 and is a functional region involved in antibacterial activity via interacting with both bacterial membrane and Lipid II [24] . In Py4, this loop exhibited an enhanced structural stability than plectasin, which could be could be a consequence of the G33A mutation since glycine is a unique amino acid without the beta carbon, is usually flexible, and can take on polypeptide backbone conformations. This mutation definitely leads to an increased structural stability in the loop of Py4. RMSF analysis revealed that several positions, particularly the N-loop and the α-helix of Py4, exhibited smaller fluctuation compared with plectasin ( Figure 2B) , indicative of the mutation-evoked conformational changes occurring at the adjacent and remote regions of the two mutational sites. Using homology modeling combined with template docking, we built a theoretic complex between Py4 and Lipid II based on that of plectasin and Lipid II ( Figure 1C,D) . Analysis of the complex structure revealed that the conserved hydrogen bond network mediating the interaction of plectasin with Lipid II [24] also exists in the Py4-Lipid II complex. The residues involved in the network include the N-terminus, His-18, Phe-2, Gly-3, Cys-4, and Cys-37 of Py4 and the D-γ-glutamate and the pyrophosphate moiety of Lipid II ( Figure 1D ), suggesting that Py4 would also target Lipid II if it has an antibacterial activity.

To investigate the potential structural effects of the mutations on Py4, we carried out molecular dynamics (MD) simulations to compare changes in structural stability and flexibility between Py4 and plectasin. The results showed that after 25 ns of simulations, their root-mean-square deviation (RMSD) curves began to deviate remarkably from each other over time (Figure 2A ). Further analyses of individual loops revealed that Py4 and plectasin both have similar RMSDs in the N-loop (residues 5-12) and the M-loop (residues [22] [23] [24] [25] [26] [27] whereas larger deviation occurred after 25-ns simulations in the C-loop (residues 31-36) (0.1 nm in Py4 and 0.4 nm in plectasin) (Figure 2A ). This indicates that this loop essentially contributes to the mutation-elicited structural deviation. In plectasin, this loop 

To experimentally investigate the structural and functional features of Py4, we used the oxidized peptide refolded from its chemically synthesized linear peptide with a purify >95%, as identified by RP−HPLC with a C 18 analytical column and MALDI−TOF ( Figure 3A,B) . The experimental m/z of 4414.310 well matched the calculated molecular weight of 4416.0 Da, indicating that the refolded Py4 formed three disulfide bridges. CD spectroscopy analysis showed that Py4 had two negative bands at 209 nm and 221 nm, respectively, and a positive band at 196 nm ( Figure 3C ). These absorbance minima and maxima respectively fell within the scope of spectroscopic signatures of the α-helix sequence of the G33A mutation since glycine is a unique amino acid without the beta carbon, is usually flexible, and can take on polypeptide backbone conformations. This mutation definitely leads to an increased structural stability in the loop of Py4. RMSF analysis revealed that several positions, particularly the N-loop and the α-helix of Py4, exhibited smaller fluctuation compared with plectasin ( Figure 2B) , indicative of the mutationevoked conformational changes occurring at the adjacent and remote regions of the two mutational sites.

To experimentally investigate the structural and functional features of Py4, we used the oxidized peptide refolded from its chemically synthesized linear peptide with a purify >95%, as identified by RP−HPLC with a C18 analytical column and MALDI−TOF ( Figure  3A,B) . The experimental m/z of 4414.310 well matched the calculated molecular weight of 4416.0 Da, indicating that the refolded Py4 formed three disulfide bridges. CD spectroscopy analysis showed that Py4 had two negative bands at 209 nm and 221 nm, respectively, and a positive band at 196 nm ( Figure 3C ). These absorbance minima and maxima respectively fell within the scope of spectroscopic signatures of the α-helix Using the classical inhibition-zone assay, we evaluated the antibacterial activity of Py4 referring to the antibacterial spectrum of plectasin [16] . The results can be summarized as follows (Table 1) : (1) Py4 exhibited an excellent antibacterial activity on Curtobacterium luteum, a psychrotrophic, plant growth-promoting endophytic bacterium [37, 38] , with a C L of 0.03 µM, and the endospore forming bacterium B. megaterium with a C L of 0.67 µM.

(2) Py4 is also highly effective on Staphylococcus warneri, a coagulase negative Staphylococcus found in human skin flora [39] with a C L of 1.06 µM. (3) Py4 showed a moderate to strong activity on other Staphylococcus species, with a C L range between 1.22 and 4.78 µM. These species include several antibiotic-resistant clinical isolates (e.g., penicillin-resistant Staphylococcus epidermidis P1389; methicillin-resistant Staphylococcus aureus P1374; methicillin-resistant coagulase negative Staphylococci P1369 and methicillin-resistant Staphylococcus aureus P1386) [19, 27] (Table 1 ). (4) Py4 exhibited no activity on Escherichia coli at the concentration range used here. 

Using the fluorescence dye-propidium iodide (PI), we assessed the membranedisruptive activity of Py4 on B. megaterium by monitoring DNA release. The results showed that the addition of this peptide caused no obvious fluorescent increase, as observed in the cells treated by vancomycin, an antibiotic inhibitor of bacterial cell wall synthesis ( Figure 4A ). Conversely, two classical membrane-active AMPs (Meucin-18 and Meucin-49) evoked such an effect. This experimental result indicates that Py4 does not kill bacteria through disrupting their membrane integrity. Subsequently, we used SEM to observe the impact of Py4 on the cellular morphology of C. luteum. We found that the untreated C. luteum cells grew with a straight rod shape whereas some treated cells by Py4 became curved rods ( Figure 4B , see Figure S1 for the full image). A similar phenomenon was also observed in the vancomycin-treated cells ( Figures 4B and S1 ), suggesting that this peptide may work in a similar manner to the inhibitors of cell-wall synthesis.

We obtained further evidence for this inference via analysis of the intracellular pool of S. warneri cell-wall synthesis precursors. By means of RP-HPLC, we identified a common emerging peak derived from the intracellular soluble molecules from both Py4-and vancomycin-treated cells, which was totally absent in the untreated cells ( Figure 4C ). MALDI-TOF mass spectrometry analysis confirmed that this accumulated soluble molecule was UDP-MurNAc-pentapeptide (abbreviated as UMP) ( Figure 4C,D) . Since UMP shares a pyrophosphate group and the γ-glutamic acid with Lipid II for interacting with the fungal and bacterial defensins (i.e., plectasin and AMSIN) [19, 24] , we used UMP as an alternative of Lipid II to study the interaction of Py4 with the cell-wall precursor. Using bio-affinity ESI-MS, a technique for the evaluation of solution-phase non-covalent interactions that has succeeded in the detection of the complex of bacterial defensing, AMSIN and UMP [19, 40] , we detected a quadruply protonated complex between Py4 and UMP at m/z 1392.092 ( Figure 4E ). This implies that this peptide kills sensitive bacteria via inhibiting their cell-wall biosynthesis.

bio-affinity ESI-MS, a technique for the evaluation of solution-phase non-covalent interactions that has succeeded in the detection of the complex of bacterial defensing, AMSIN and UMP [19, 40] , we detected a quadruply protonated complex between Py4 and UMP at m/z 1392.092 ( Figure 4E ). This implies that this peptide kills sensitive bacteria via inhibiting their cell-wall biosynthesis. 

To explore the potential therapeutic value of Py4, we evaluated its two important properties, namely hemolysis and serum stability, which are highly relevant to the therapeutic efficacy of a peptide drug. In the hemolysis assay, we found that Py4 showed no significant hemolysis on mouse blood cells at a concentration range from 3.125 to 25 μM using 2-fold serial dilutions. In contrast, the positive control peptide-Meucin-18showed strong hemolysis at 25 μM ( Figure 5A ). In the serum stability assay performed using the inhibition-zone method to determine the effect of incubation in water or serum on the antibacterial activity, we found that Py4 retained its full antibacterial activity after 

To explore the potential therapeutic value of Py4, we evaluated its two important properties, namely hemolysis and serum stability, which are highly relevant to the therapeutic efficacy of a peptide drug. In the hemolysis assay, we found that Py4 showed no significant hemolysis on mouse blood cells at a concentration range from 3.125 to 25 µM using 2-fold serial dilutions. In contrast, the positive control peptide-Meucin-18-showed strong hemolysis at 25 µM ( Figure 5A ). In the serum stability assay performed using the inhibition-zone method to determine the effect of incubation in water or serum on the antibacterial activity, we found that Py4 retained its full antibacterial activity after 24-and 48-h incubation in both water and the undiluted fresh mouse serum at 37 • C ( Figure 5B ). These data indicate that Py4 is a non-hemolytic defensin with high mammalian serum stability.

24-and 48-h incubation in both water and the undiluted fresh mouse serum at 37 °C (Figure 5B) . These data indicate that Py4 is a non-hemolytic defensin with high mammalian serum stability. 

In this work, we report on the structural and functional characterization of a new fDLP (Py4). By using the chemically synthetic peptide, we confirmed that Py4 adopts a CSαβ structure with activity against multiple Gram-positive bacteria. These results are perhaps not unexpected given that Py4 has only two point mutations compared with plectasin ( Figure 1A) and notably, the residues previously identified to be involved in a direct contact of plectasin with the bacterial Lipid II [24] are completely conserved in Py4. However, as mentioned previously, mutations at position 33 from the glycine to any non-glycine amino acids including alanine led to the activity loss of plectasin, implying that the alanine or any other non-glycine residues is deleterious in this genetic background, restraining its mutation. Conversely, in Py4, the G33A mutation does not diminish its antibacterial activity, implying that an alanine at this position is allowable. This raises an interesting evolutionary question regarding how the plectasin otholog Py4 can remove such mutational restraint to maintain its antibacterial activity after species divergence. Our prior study has found that an internal epistatic interaction in Crem-5, a nematode-sourced antifungal defensin with a similar structure to that of Py4, may exert a role in restraining the evolution of its certain site [41] . Such restraint is removed in its otholog Clat-5 through introducing one mutation at another site to relieve the epistatic control [41] . We believe that this also likely occurs in the evolution of Py4. In this evolutionary scenario, the Q14K mutation introduces a new genetic background into the peptide, permitting the occurrence of G33A so that the antibacterial activity remains ( Figure 6 ). This kind of intramolecular epistasis has been found to be able to exert a strong influence on trajectories of protein evolution [42] .

Such mutations described above clearly change the dynamics behavior of plectasin and Py4 (Figure 2 ). In particular, the G33A mutation significantly increased the rigidity of the molecule. This could explain the activity loss in the Gly-33 mutants of plectasin since rational design of peptides has indicated that a more rigid defensin structure is often associated with a lower activity [43] . However, we found that although Py4 has a more rigid structure, it exerts an overall comparable anti-S. aureus activity with plectasin [16] (Table  1 ). This may be explained by the compensatory mutation at position 14 (Q14K) (Figure 6 ). In line with this explanation, engineering of a Lys into this position has been found to 

In this work, we report on the structural and functional characterization of a new fDLP (Py4). By using the chemically synthetic peptide, we confirmed that Py4 adopts a CSαβ structure with activity against multiple Gram-positive bacteria. These results are perhaps not unexpected given that Py4 has only two point mutations compared with plectasin ( Figure 1A) and notably, the residues previously identified to be involved in a direct contact of plectasin with the bacterial Lipid II [24] are completely conserved in Py4. However, as mentioned previously, mutations at position 33 from the glycine to any non-glycine amino acids including alanine led to the activity loss of plectasin, implying that the alanine or any other non-glycine residues is deleterious in this genetic background, restraining its mutation. Conversely, in Py4, the G33A mutation does not diminish its antibacterial activity, implying that an alanine at this position is allowable. This raises an interesting evolutionary question regarding how the plectasin otholog Py4 can remove such mutational restraint to maintain its antibacterial activity after species divergence. Our prior study has found that an internal epistatic interaction in Crem-5, a nematode-sourced antifungal defensin with a similar structure to that of Py4, may exert a role in restraining the evolution of its certain site [41] . Such restraint is removed in its otholog Clat-5 through introducing one mutation at another site to relieve the epistatic control [41] . We believe that this also likely occurs in the evolution of Py4. In this evolutionary scenario, the Q14K mutation introduces a new genetic background into the peptide, permitting the occurrence of G33A so that the antibacterial activity remains ( Figure 6 ). This kind of intramolecular epistasis has been found to be able to exert a strong influence on trajectories of protein evolution [42] .

Such mutations described above clearly change the dynamics behavior of plectasin and Py4 (Figure 2 ). In particular, the G33A mutation significantly increased the rigidity of the molecule. This could explain the activity loss in the Gly-33 mutants of plectasin since rational design of peptides has indicated that a more rigid defensin structure is often associated with a lower activity [43] . However, we found that although Py4 has a more rigid structure, it exerts an overall comparable anti-S. aureus activity with plectasin [16] (Table 1) . This may be explained by the compensatory mutation at position 14 (Q14K) (Figure 6 ). In line with this explanation, engineering of a Lys into this position has been found to exert a positive role on the antibacterial activity of plectasin. This could compensate for the loss caused by the G33A mutation-evoked rigidity increase in Py4 and thus allows its occurrence in Py4, as previously mentioned. Although the ecological significance of the mutations to its fungal host and related physical interaction between the two positions remain to be established, it appears to be clear that even minor mutations in fDLPs could be of certain evolutionary and functional significance given their occurrence in a new environment following species divergence [16, 25, 44] . Therefore, for a newfound fDLP even with few mutations with the known ones, it may still be worth further investigation if we consider their new genetic background, likely conferring new values as templates for protein engineering.

J . Fungi 2022, 8, 174 11 of 14 the loss caused by the G33A mutation-evoked rigidity increase in Py4 and thus allows its occurrence in Py4, as previously mentioned. Although the ecological significance of the mutations to its fungal host and related physical interaction between the two positions remain to be established, it appears to be clear that even minor mutations in fDLPs could be of certain evolutionary and functional significance given their occurrence in a new environment following species divergence [16, 25, 44] . Therefore, for a newfound fDLP even with few mutations with the known ones, it may still be worth further investigation if we consider their new genetic background, likely conferring new values as templates for protein engineering. The arrow points to the position accounting for differential genetic backgrounds between plectasin and Py4. The "*" denotes that besides the mutant G33A, other non-glycine mutants at this position also showed no activity [24] . "+", activity; "-", no activity".

A key challenge in the development of AMPs as antimicrobials is their hemolytic effect on human and mammalian erythrocytes, which clearly stems from their fundamental detergent-like properties causing membrane disruption and cellular toxicity [45] [46] [47] [48] . This has been seen in many AMPs such as Melittin and the Meucin series [31, 32, 48, 49] . In addition, many AMPs are unstable when incubated in human and mammalian serums. For example, the antimicrobial activity of human AMPs is inactivated by both human and fetal bovine serums [50] [51] [52] . This might be related to their physiological roles being limited to the defense of local microenvironment other than delivery to the systemic circulation [19, 47] . Conversely, Py4 has two striking properties that are superior to these AMPs: (1) It is of high stably in undiluted mouse serum where it retains full antibacterial activity for a long time; and (2) Py4 is a non-hemolytic peptide. This can be explained by the lack of an overall amphiphilic architecture in Py4, making it impossible to disrupt the bacterial membrane.

Of the Py4-sensitive Staphylococcus, S. warneri is a commensal skin bacterium that is an opportunistic pathogen that can cause serious diseases in humans such as native valve endocarditis, ventriculoatrial shunt and ventriculoperitoneal shunt infections, meningitis, botryomycosis, urinary tract infection, multifocal discitis, septic arthritis, and vertebral osteomyelitis [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . Therefore, in addition to the potential value of Py4 against the clinical isolates of Staphylococcus, its potent activity on S. warneri by targeting the cell-wall biosynthesis should be further explored.

As a natural variant of plectasin, Py4 exhibits a unique dynamic behavior unlike the prototypical fungal defensin and shows excellent antibacterial activity, particular-ly on some Staphylococcus species. Compared with many animal-and human-derived AMPs, Py4 shows two important properties relevant to its therapeutic efficacy, that is, no toxicity on mammalian erythrocytes and high stability in undiluted mammalian serum. In addition, similar to other fungal defensins, Py4 binds to the bacterial cell-wall intermediate Figure 6 . Evidence for intramolecular epistasis in fDLPs. Small dots represent identical residues to plectasin. Positions showing differences in the peptides are boxed and the mutated residues relative to plectasin are colored in red. Positions involved in intramolecular epistasis are linked by one line. The arrow points to the position accounting for differential genetic backgrounds between plectasin and Py4. The "*" denotes that besides the mutant G33A, other non-glycine mutants at this position also showed no activity [24] . "+", activity; "-", no activity".

A key challenge in the development of AMPs as antimicrobials is their hemolytic effect on human and mammalian erythrocytes, which clearly stems from their fundamental detergent-like properties causing membrane disruption and cellular toxicity [45] [46] [47] [48] . This has been seen in many AMPs such as Melittin and the Meucin series [31, 32, 48, 49] . In addition, many AMPs are unstable when incubated in human and mammalian serums. For example, the antimicrobial activity of human AMPs is inactivated by both human and fetal bovine serums [50] [51] [52] . This might be related to their physiological roles being limited to the defense of local microenvironment other than delivery to the systemic circulation [19, 47] . Conversely, Py4 has two striking properties that are superior to these AMPs: (1) It is of high stably in undiluted mouse serum where it retains full antibacterial activity for a long time; and (2) Py4 is a non-hemolytic peptide. This can be explained by the lack of an overall amphiphilic architecture in Py4, making it impossible to disrupt the bacterial membrane.

Of the Py4-sensitive Staphylococcus, S. warneri is a commensal skin bacterium that is an opportunistic pathogen that can cause serious diseases in humans such as native valve endocarditis, ventriculoatrial shunt and ventriculoperitoneal shunt infections, meningitis, botryomycosis, urinary tract infection, multifocal discitis, septic arthritis, and vertebral osteomyelitis [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . Therefore, in addition to the potential value of Py4 against the clinical isolates of Staphylococcus, its potent activity on S. warneri by targeting the cell-wall biosynthesis should be further explored.

As a natural variant of plectasin, Py4 exhibits a unique dynamic behavior unlike the prototypical fungal defensin and shows excellent antibacterial activity, particular-ly on some Staphylococcus species. Compared with many animal-and human-derived AMPs, Py4 shows two important properties relevant to its therapeutic efficacy, that is, no toxicity on mammalian erythrocytes and high stability in undiluted mammalian serum. In addition, similar to other fungal defensins, Py4 binds to the bacterial cell-wall intermediate Lipid II to achieve its antibiotic effect, a mechanism that may reduce and delay the occurrence of bacterial resistance [19] . All these findings imply that Py4 is a promising candidate for developing into an anti-Staphylococcus drug. The discovery that few point mutations can cause a significant structural dynamics change in fungal defensins highlights the impor-tance of the work on continuous mining of fDLPs from the fungal genome resource and experimental evaluation of their activity and action modes through the methods described here, which should be encouraged. This will offer a platform for the future development of lead antimicrobials in the age of resistance. Finally, structural and functional studies of newfound fDLPs will help to shed light on how evolution has shaped their mutations in the context of epistasis.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/jof8020174/s1, Figure S1 : Scanning electron microscopic observation of Py4-induced C. luteum deformation. 

Antimicrobial peptides: Application informed by evolution

The value of antimicrobial peptides in the age of resistance

An overview of antimicrobial peptides and the latest advances in their development

Antimicrobial host defence peptides: Functions and clinical potential

Membrane-active host defense peptides-Challenges and perspectives for the development of novel anticancer drugs

Outer membrane protein I of Pseudomonas aeruginosa is a target of cationic antimicrobial peptide/protein

Docking on lipid II-A widespread mechanism for potent bactericidal activities of antibiotic peptides

Sequence and specificity of two antibacterial proteins involved in insect immunity

The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils

Proline-arginine rich (PR-39) cathelicidin: Structure, expression and functional implication in intestinal health

Antimicrobial peptides in Drosophila: Structures, activities and gene regulation

Protegrin-1 enhances bacterial killing in thermally injured skin

The defensins consist of two independent, convergent protein superfamilies

Evolutionary origin of β-defensins

Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus

Phylogenetic distribution, functional epitopes and evolution of the CSαβ superfamily

AdDLP, a bacterial defensin-like peptide exhibits anti-Plasmodium activity

Adaptively evolved human oral Actinomyces-sourced defensins show therapeutic potential

Defensins of vertebrate animals

Did cis-and trans-defensins derive from a common ancestor

Discovery of six families of defensin-like peptides in fungi provides insights for origin and evolution of the CSαβ-type defensins

Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic

Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II

The fungal defensin family enlarged

Eurocin, a new fungal defensin: Structure, lipid binding, and its mode of action

Dermatophytic defensin with antiinfective potential

Template-based structure modeling of protein-protein interactions

A fungal defensin targets the SARS-CoV-2 spike receptor-binding domain

Quantification of antimicrobial activity, using the inhibition-zone assay

Structural and functional characterization of two genetically related meucin peptides highlights evolutionary divergence and convergence in antimicrobial peptides

Meucin-49, a multifunctional scorpion venom peptide with bactericidal synergy with neurotoxins

The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation

Improving on nature's defenses: Optimization & high throughput screening of antimicrobial peptides

In vitro and in vivo characterization of a new recombinant antimicrobial peptide, MP1102, against methicillin-resistant Staphylococcus aureus

Epistasis and intramolecular networks in protein evolution

A cold-active extracellular metalloprotease from Curtobacterium luteum (MTCC 7529): Enzyme production and characterization

Plant growth-promoting endophytic bacteria augment growth and salinity tolerance in rice plants

Complete genome of the solvent-tolerant Staphylococcus warneri Strain SG1

Using electrospray ionisation mass spectrometry to study non-covalent interactions

Evolution-Based Protein Engineering for Antifungal Peptide Improvement

Compensatory mutations and epistasis for protein function

Rational design of peptides active against the gram positive bacteria Staphylococcus aureus

The genome and development-dependent transcriptomes of Pyronema confluens: A window into fungal evolution

New approaches in peptide antibiotics

Host defense peptides: Front-line immunomodulators

Antimicrobial peptides of multicellular organisms: My perspective

Antimicrobial peptides as therapeutic agents: Opportunities and challenges

Mesobuthus venom-derived antimicrobial peptides possess intrinsic multifunctionality and differential potential as drugs

Human neutrophil defensin and serpins form complexes and inactivate each other

Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37

Inhibition of SARS-CoV-2 infection by human defensin HNP1 and retrocyclin RC-101

Vertebral osteomyelitis due to Staphylococcus warneri

Ventriculoatrial shunt infection caused by Staphylococcus warneri: Case report and review

Significant infection caused by Staphylococcus warneri

Multifocal discitis caused by Staphylococcus warneri

Characterization of 26 Staphylococcus warneri isolates from orthopedic infections

Staphylococcus warneri meningitis in a patient with Strongyloides stercoralis hyperinfection and lymphoma: First report of a case

Staphylococcus warneri ventriculoperitoneal shunt infection: Failure of diagnosis by ventricular CSF sampling

Septic arthritis due to Staphylococcus warneri: A diagnostic challenge

Donoiu, I. Native valve endocarditis with Staphylococcus warneri

Staphylococcus warneri: Skin commensal and a rare cause of urinary tract infection

Native valve endocarditis caused by Staphylococcus warneri: An unusual presentation

Native mitral valve infective endocarditis caused by Staphylococcus warneri: A case-based review

Botryomycosis caused by Staphylococcus warneri: The first case reported

The authors gratefully acknowledge Alexandre Bonvin for providing the computational model of the plectasin-Lipid II complex structure.

The authors declare no competing financial interest.

3D: three-dimensional; α-CHCA, α-acyano-4-hydroxycinnamic acid; AITD, ancient invertebrate-type defensin; AMP, antimicrobial peptide; CD, circular dichroism; CITD, antibacterial classical insect-type defensin; C L , lethal concentration; CSαβ, cysteine-stabilized α-helical and β-sheet; fDLP, fungal defensin-like peptide; MALDI-TOF MS, matrix-assisted laser desorption/ionization time of flight mass spectrometry; MW, molecular weight; OPLS, optimized potential for liquid simulations; PG-1, protegrin-1; PBS, phosphate buffered saline; PI, propidium iodide; PITD, antifungal plant/insect-type defensin; Py4, Pyronesin4; RMSD, root-mean-square deviation; RMSF, root-mean-square fluctuation; RP-HPLC, reverse phase-high performance liquid chromatography; SEM, scanning electron microscope; UMP, UDP-MurNAc-pentapeptide.